Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 43 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Atezolizumab in addition to paclitaxel, carboplatin and bevacizumab for epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer – first-line	Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) , Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2019	View \| Download
AT406 (Debio 1143) for Ovarian Cancer – neoadjuvant therapy	Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) , Xevinapant (Debio 1143; AT-406)	Ovarian cancer	Female Reproductive Cancer	2018	View \| Download
Alpelisib and Olaparib for treating platinum-resistant or refractory BRCA wild-type ovarian cancer	Alpelisib (BYL719; Piqray) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Ovarian cancer	Female Reproductive Cancer	2022	View \| Download